| Sex-associated molecular differences for cancer immunotherapy Y Ye, Y Jing, L Li, GB Mills, L Diao, H Liu, L Han Nature communications 11 (1), 1779, 2020 | 197 | 2020 |
| Multi-omics prediction of immune-related adverse events during checkpoint immunotherapy Y Jing, J Liu, Y Ye, L Pan, H Deng, Y Wang, Y Yang, L Diao, SH Lin, ... Nature communications 11 (1), 4946, 2020 | 156 | 2020 |
| Comprehensive characterization of circular RNAs in~ 1000 human cancer cell lines H Ruan, Y Xiang, J Ko, S Li, Y Jing, X Zhu, Y Ye, Z Zhang, T Mills, J Feng, ... Genome medicine 11, 1-14, 2019 | 140 | 2019 |
| Exome sequencing of hepatoblastoma reveals novel mutations and cancer genes in the Wnt pathway and ubiquitin ligase complex D Jia, R Dong, Y Jing, D Xu, Q Wang, L Chen, Q Li, Y Huang, Y Zhang, ... Hepatology 60 (5), 1686-1696, 2014 | 122 | 2014 |
| Deubiquitinase USP13 dictates MCL1 stability and sensitivity to BH3 mimetic inhibitors S Zhang, M Zhang, Y Jing, X Yin, P Ma, Z Zhang, X Wang, W Di, ... Nature communications 9 (1), 215, 2018 | 120 | 2018 |
| BET bromodomain inhibition as a therapeutic strategy in ovarian cancer by downregulating FoxM1 Z Zhang, P Ma, Y Jing, Y Yan, MC Cai, M Zhang, S Zhang, H Peng, ZL Ji, ... Theranostics 6 (2), 219, 2016 | 99 | 2016 |
| miR-192, a prognostic indicator, targets the SLC39A6/SNAIL pathway to reduce tumor metastasis in human hepatocellular carcinoma J Lian, Y Jing, Q Dong, L Huan, D Chen, C Bao, Q Wang, F Zhao, J Li, ... Oncotarget 7 (3), 2672, 2015 | 99 | 2015 |
| Association between sex and immune-related adverse events during immune checkpoint inhibitor therapy Y Jing, Y Zhang, J Wang, K Li, X Chen, J Heng, Q Gao, Y Ye, Z Zhang, ... JNCI: Journal of the National Cancer Institute 113 (10), 1396-1404, 2021 | 77 | 2021 |
| Simultaneous evolutionary expansion and constraint of genomic heterogeneity in multifocal lung cancer P Ma, Y Fu, MC Cai, Y Yan, Y Jing, S Zhang, M Chen, J Wu, Y Shen, ... Nature communications 8 (1), 823, 2017 | 76 | 2017 |
| Harnessing big data to characterize immune-related adverse events Y Jing, J Yang, DB Johnson, JJ Moslehi, L Han Nature Reviews Clinical Oncology 19 (4), 269-280, 2022 | 75 | 2022 |
| Preclinical efficacy and molecular mechanism of targeting CDK7-dependent transcriptional addiction in ovarian cancer Z Zhang, H Peng, X Wang, X Yin, P Ma, Y Jing, MC Cai, J Liu, M Zhang, ... Molecular cancer therapeutics 16 (9), 1739-1750, 2017 | 75 | 2017 |
| Amplification of MPZL1/PZR promotes tumor cell migration through Src-mediated phosphorylation of cortactin in hepatocellular carcinoma D Jia, Y Jing, Z Zhang, L Liu, J Ding, F Zhao, C Ge, Q Wang, T Chen, ... Cell research 24 (2), 204-217, 2014 | 73 | 2014 |
| Advancing CAR T cell therapy through the use of multidimensional omics data J Yang, Y Chen, Y Jing, MR Green, L Han Nature Reviews Clinical Oncology 20 (4), 211-228, 2023 | 59 | 2023 |
| Association of antibiotic treatment with immune-related adverse events in patients with cancer receiving immunotherapy Y Jing, X Chen, K Li, Y Liu, Z Zhang, Y Chen, Y Liu, Y Wang, SH Lin, ... Journal for immunotherapy of cancer 10 (1), 2022 | 57 | 2022 |
| Comprehensive genomic profiling of neuroendocrine bladder cancer pinpoints molecular origin and potential therapeutics P Shen, Y Jing, R Zhang, MC Cai, P Ma, H Chen, G Zhuang Oncogene 37 (22), 3039-3044, 2018 | 57 | 2018 |
| Baseline immunity and impact of chemotherapy on immune microenvironment in cervical cancer Y Zhang, M Yu, Y Jing, J Cheng, C Zhang, L Cheng, H Lu, MC Cai, J Wu, ... British Journal of Cancer 124 (2), 414-424, 2021 | 54 | 2021 |
| Stroma-associated master regulators of molecular subtypes predict patient prognosis in ovarian cancer S Zhang, Y Jing, M Zhang, Z Zhang, P Ma, H Peng, K Shi, WQ Gao, ... Scientific reports 5 (1), 16066, 2015 | 53 | 2015 |
| Adaptive and acquired resistance to EGFR inhibitors converge on the MAPK pathway P Ma, Y Fu, M Chen, Y Jing, J Wu, K Li, Y Shen, JX Gao, M Wang, X Zhao, ... Theranostics 6 (8), 1232, 2016 | 52 | 2016 |
| SERPINA5 inhibits tumor cell migration by modulating the fibronectin–integrin β1 signaling pathway in hepatocellular carcinoma Y Jing, D Jia, CM Wong, IOL Ng, Z Zhang, L Liu, Q Wang, F Zhao, J Li, ... Molecular oncology 8 (2), 366-377, 2014 | 52 | 2014 |
| APAatlas: decoding alternative polyadenylation across human tissues W Hong, H Ruan, Z Zhang, Y Ye, Y Liu, S Li, Y Jing, H Zhang, L Diao, ... Nucleic acids research 48 (D1), D34-D39, 2020 | 51 | 2020 |
Guanglei ZhuangShanghai Jiao Tong UniversityVerified email at renji.com
